Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer

Yasuhiro Tada, Akira Yokomizo, Masaki Shiota, Toshiyuki Tsunoda, Christoph Plass, Seiji Naito

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The development of resistance to cisplatin during treatment of bladder cancer constitutes a major obstacle to curing bladder cancer. The identification of epigenetic biomarker molecules for cisplatin resistance and the elucidation of the function of the identified genes in bladder cancer will provide useful information. We found that the candidate gene TLX3 was unmethylated in cisplatin sensitive cells and methylated in resistant cells. The suppression of TLX3 expression using TLX3-specific shRNA in parental cells increased cisplatin resistance. Contrarily, overexpression of TLX3 in resistant cells induced increased sensitivity to cisplatin. We found that 22 (21%) out of 110 clinical samples of bladder cancer showed the methylated pattern using the COBRA assay in TLX3. We found a correlation between TLX3 methylation and the sensitivity to cisplatin in the clinical samples by SDI test. Cisplatin sensitivity was closely associated with the methylation status of TLX3. These findings showed that the TLX3 methylation may be useful as a novel biomarker for cisplatin resistance and can be used to design therapies to counteract the resistance against cisplatin in bladder cancer.

Original languageEnglish
Pages (from-to)727-733
Number of pages7
JournalInternational journal of oncology
Volume39
Issue number3
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

T-Cell Leukemia
Homeobox Genes
DNA Methylation
Urinary Bladder Neoplasms
Cisplatin
Methylation
Biomarkers
Epigenomics
Small Interfering RNA
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer. / Tada, Yasuhiro; Yokomizo, Akira; Shiota, Masaki; Tsunoda, Toshiyuki; Plass, Christoph; Naito, Seiji.

In: International journal of oncology, Vol. 39, No. 3, 01.09.2011, p. 727-733.

Research output: Contribution to journalArticle

Tada, Yasuhiro ; Yokomizo, Akira ; Shiota, Masaki ; Tsunoda, Toshiyuki ; Plass, Christoph ; Naito, Seiji. / Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer. In: International journal of oncology. 2011 ; Vol. 39, No. 3. pp. 727-733.
@article{39f9abd6a6b249c587cd17459d38fbd0,
title = "Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer",
abstract = "The development of resistance to cisplatin during treatment of bladder cancer constitutes a major obstacle to curing bladder cancer. The identification of epigenetic biomarker molecules for cisplatin resistance and the elucidation of the function of the identified genes in bladder cancer will provide useful information. We found that the candidate gene TLX3 was unmethylated in cisplatin sensitive cells and methylated in resistant cells. The suppression of TLX3 expression using TLX3-specific shRNA in parental cells increased cisplatin resistance. Contrarily, overexpression of TLX3 in resistant cells induced increased sensitivity to cisplatin. We found that 22 (21{\%}) out of 110 clinical samples of bladder cancer showed the methylated pattern using the COBRA assay in TLX3. We found a correlation between TLX3 methylation and the sensitivity to cisplatin in the clinical samples by SDI test. Cisplatin sensitivity was closely associated with the methylation status of TLX3. These findings showed that the TLX3 methylation may be useful as a novel biomarker for cisplatin resistance and can be used to design therapies to counteract the resistance against cisplatin in bladder cancer.",
author = "Yasuhiro Tada and Akira Yokomizo and Masaki Shiota and Toshiyuki Tsunoda and Christoph Plass and Seiji Naito",
year = "2011",
month = "9",
day = "1",
doi = "10.3892/ijo.2011.1049",
language = "English",
volume = "39",
pages = "727--733",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer

AU - Tada, Yasuhiro

AU - Yokomizo, Akira

AU - Shiota, Masaki

AU - Tsunoda, Toshiyuki

AU - Plass, Christoph

AU - Naito, Seiji

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The development of resistance to cisplatin during treatment of bladder cancer constitutes a major obstacle to curing bladder cancer. The identification of epigenetic biomarker molecules for cisplatin resistance and the elucidation of the function of the identified genes in bladder cancer will provide useful information. We found that the candidate gene TLX3 was unmethylated in cisplatin sensitive cells and methylated in resistant cells. The suppression of TLX3 expression using TLX3-specific shRNA in parental cells increased cisplatin resistance. Contrarily, overexpression of TLX3 in resistant cells induced increased sensitivity to cisplatin. We found that 22 (21%) out of 110 clinical samples of bladder cancer showed the methylated pattern using the COBRA assay in TLX3. We found a correlation between TLX3 methylation and the sensitivity to cisplatin in the clinical samples by SDI test. Cisplatin sensitivity was closely associated with the methylation status of TLX3. These findings showed that the TLX3 methylation may be useful as a novel biomarker for cisplatin resistance and can be used to design therapies to counteract the resistance against cisplatin in bladder cancer.

AB - The development of resistance to cisplatin during treatment of bladder cancer constitutes a major obstacle to curing bladder cancer. The identification of epigenetic biomarker molecules for cisplatin resistance and the elucidation of the function of the identified genes in bladder cancer will provide useful information. We found that the candidate gene TLX3 was unmethylated in cisplatin sensitive cells and methylated in resistant cells. The suppression of TLX3 expression using TLX3-specific shRNA in parental cells increased cisplatin resistance. Contrarily, overexpression of TLX3 in resistant cells induced increased sensitivity to cisplatin. We found that 22 (21%) out of 110 clinical samples of bladder cancer showed the methylated pattern using the COBRA assay in TLX3. We found a correlation between TLX3 methylation and the sensitivity to cisplatin in the clinical samples by SDI test. Cisplatin sensitivity was closely associated with the methylation status of TLX3. These findings showed that the TLX3 methylation may be useful as a novel biomarker for cisplatin resistance and can be used to design therapies to counteract the resistance against cisplatin in bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=79959970381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959970381&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.1049

DO - 10.3892/ijo.2011.1049

M3 - Article

C2 - 21617853

AN - SCOPUS:79959970381

VL - 39

SP - 727

EP - 733

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -